Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 4, 2008, Pages 418-425

  Armand, Philippe ^a   Kim, Haesook T ^a   Ho, Vincent T ^a   Cutler, Corey S ^a   Koreth, John ^a   Antin, Joseph H ^a   LaCasce, Ann S ^a   Jacobsen, Eric D ^a   Fisher, David C ^a   Brown, Jennifer R ^a   Canellos, George P ^a   Freedman, Arnold S ^a   Soiffer, Robert J ^a   Alyea, Edwin P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Allogeneic stem cell transplantation; Hodgkin lymphoma; Mantle cell lymphoma; Non Hodgkin lymphoma; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOSPORIN; FLUDARABINE; LACTATE DEHYDROGENASE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CENTER; CANCER MORTALITY; CANCER REGRESSION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE COURSE; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; FEMALE; HISTOLOGY; HODGKIN DISEASE; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME; UNITED STATES; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 40649116201     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.01.008     Document Type: Article

References (26)

1. Schmitz N., Dreger P., Glass B., and Sureda A. Allogeneic transplantation in lymphoma: current status. Haematologica 92 (2007) 1533-1548
2. Peniket A.J., Ruiz de Elvira M.C., Taghipour G., et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31 (2003) 667-678
3. van Besien K., Loberiza Jr. F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 (2003) 3521-3529
4. Bierman P.J., Sweetenham J.W., Loberiza Jr. F.R., et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 21 (2003) 3744-3753
5. Khouri I.F., Saliba R.M., Lee M.-S., et al. Longer follow-up confirms a low relapse rate after non-myeloablative allogeneic transplantation (NMT) for non-Hodgkin's lymphoma (NHL), including patients with PET or gallium-avid disease. Blood 106 (2005) 44
6. Brown J.R., Kim H.T., Li S., et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12 (2006) 1056-1064
7. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
8. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
9. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1140-1154
10. Fine J., and Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999) 496-509
11. Anderlini P., Saliba R., Acholonu S., et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35 (2005) 943-951
12. Anderson J.E., Litzow M.R., Appelbaum F.R., et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 11 (1993) 2342-2350
13. Milpied N., Fielding A.K., Pearce R.M., Ernst P., and Goldstone A.H. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14 (1996) 1291-1296
14. Akpek G., Ambinder R.F., Piantadosi S., et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 19 (2001) 4314-4321
15. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104 (2004) 3865-3871
16. Maris M.B., Sandmaier B.M., Storer B., et al. Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. (ASH Annual Meeting Abstracts). Blood 106 (2005) 1130
17. Van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 20 (2006) 235-244
18. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia (2007)
19. Rezvani A.R., Storer B., Maris M., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol (2007)
20. Baron F., Storb R., Storer B., et al. Allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning after failed myeloablative HCT: factors affecting outcomes. (ASH Annual Meeting Abstracts). Blood 106 (2005) 1143
21. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316
22. Faulkner R.D., Craddock C., Byrne J.L., et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 103 (2004) 428-434
23. Doocey R.T., Toze C.L., Connors J.M., et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131 (2005) 223-230
24. Kiss T.L., Mollee P., Lazarus H.M., and Lipton J.H. Stem cell transplantation for mantle cell lymphoma: if, when and how?. Bone Marrow Transplant 36 (2005) 655-661
25. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004) 3535-3542
26. Robinson S.P., Schmitz N., Taghipour G., and Sureda A. Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant related mortality and a poor outcome in patients with chemoresistant disease. (ASH Annual Meeting Abstracts). Blood 104 (2004) 2260